Phase I and pharmacologie study of liposomal daunorubicin (DaunoXome) |
| |
| Authors: | Perry Guaglianone Kenneth Chan Eduardo DelaFlor-Weiss Rosemarie Hanisch Susan Jeffers Desh Sharma Franco Muggia |
| |
| Institution: | (1) Division of Medical Oncology, University of Southern California, 90033 Los Angeles, California;(2) Comprehensive Cancer Center, The Ohio State University, Room 309, 410 W. 12th Avenue, Columbus, Ohio, USA |
| |
| Abstract: | Summary We have completed a phase I and pharmacology study of liposomally-encapsulated daunorubicin (DaunoXome). Of 32 patients entered, 30 were evaluable. No toxicity was encountered at the initial doseescalation steps from 10 to 60 mg/m2. At 80 mg/m2, two patients manifested grade 2 neutropenia. At least grade 3 neutropenia occurred in all patients receiving 120 mg/m2. Alopecia and subjective intolerance were mild. Cardiotoxicity was not observed except for an episode of arrhythmia in a patient with lung cancer and prior radiation. Only one minor objective response was observed in this population of refractory solid tumors. Pharmacokinetics differed from those of the free drug with no detection of daunorubicinol. We recommend future phase II studies with a dose of 100 mg/m2 in previously treated and 120 mg/m2 of DaunoXome in previously untreated patients with solid tumors.EDW is supported in part by ACS award 92-14-1 |
| |
| Keywords: | daunorubicin liposomes pharmacokinetics |
| 本文献已被 SpringerLink 等数据库收录！ |
|
